Generation and characterization of a murine model of bietti crystalline dystrophy

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 9, 2014, Pages 5572-5581

  Lockhart, Catherine M ^a   Nakano, Mariko ^a   Rettie, Allan E ^a   Kelly, Edward J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Bietti crystalline dystrophy; CYP4V2; Preclinical model

Indexed keywords

ATROPINE; FATTY ACID BINDING PROTEIN; POLYUNSATURATED FATTY ACID; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BIETTI CRYSTALLINE DYSTROPHY; CONTROLLED STUDY; CYP4V3 GENE; DYSLIPIDEMIA; EMBRYONIC STEM CELL; EYE FUNDUS; GENE; GENE MUTATION; GENETIC VARIABILITY; HISTOLOGY; KNOCKOUT GENE; LIVER MICROSOME; MASS FRAGMENTOGRAPHY; MOUSE; MURINAE; NONHUMAN; NULL ALLELE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ANIMAL; BLOOD; C57BL MOUSE; CONGENITAL CORNEA DYSTROPHY; CYP4V2; DISEASE MODEL; PATHOLOGY; PRECLINICAL MODEL; RETINA DISEASE;

BIETTI CRYSTALLINE DYSTROPHY; CYP4V2; PRECLINICAL MODEL;

ANIMALS; BLOTTING, WESTERN; CORNEAL DYSTROPHIES, HEREDITARY; DISEASE MODELS, ANIMAL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; LIPIDS; MICE; MICE, INBRED C57BL; RETINAL DISEASES;

EID: 84908108215     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13717     Document Type: Article

References (58)

1. Bietti G. Ueber familiaeres vorkommen von “retinitis punctata albescens” (verbunden mit “dystrophia marginalis cristallinea corneae”), glitzern des glaskoerpers und anderen degenerativen augenveraenderungen. Klin Monbl Augenheilkd. 1937; 99:21.
2. National Eye Institute, National Institutes of Health. Facts about Bietti’s crystalline dystrophy. Available at: http://www. nei.nih.gov/Health/biettis/index.asp. Accessed August 7, 2014.
3. Kaiser-Kupfer MI, Chan CC, Markello TC, et al. Clinical biochemical and pathologic correlations in Bietti’s crystalline dystrophy. Am J Ophthalmol. 1994;118:569–582.
4. Mataftsi A, Zografos L, Milla E, Secretan M, Munier FL. Bietti’s crystalline corneoretinal dystrophy: a cross-sectional study. Retina. 2004;24:416–426.
5. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368:1795–1809.
6. Li A, Jiao X, Munier FL, et al. Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V 2. Am J Hum Genet. 2004;74:817–826.
7. Fong AM, Koh A, Lee K, Ang CL. Bietti’s crystalline dystrophy in Asians: clinical, angiographic and electrophysiological characteristics. Int Ophthalmol. 2008;29:459–470.
8. Ayata A, Tathpinar S, Unal M, Ersanli D, Bilge AH. Autofluorescence and OCT features of Bietti’s crystalline dystrophy. Br J Ophthalmol. 2008;92:718–720.
9. Chung JK, Shin JH, Jeon BR, Ki CS, Park TK. Optical coherence tomographic findings of crystal deposits in the lens and cornea in Bietti crystalline corneoretinopathy associated with mutation in the CYP4V2 gene. Jpn J Ophthalmol. 2013;57:447–450.
10. Garcia-Garcia G-P, Lopez-Garrido M-P, Martinez-Rubio M, Moya- Moya M-A, Belmonte-Martinez J, Escribano J. Genotypephenotype analysis of Bietti crystalline dystrophy in a family with the CYP4V2 Ile111Thr mutation. Cornea. 2013;32:1002–1008.
11. Rossi S, Testa F, Li A, et al. Clinical and genetic features in Italian Bietti crystalline dystrophy patients. Br J Ophthalmol. 2012;97:174–179.
12. Rossi S, Testa F, Li A, et al. An atypical form of Bietti crystalline dystrophy. Ophthalmic Genet. 2011;32:118–121.
13. Li A, Jiao X, Munier FL, et al. Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V 2. Am J Hum Genet. 2004;74:817–826.
14. Nakano M, Kelly EJ, Wiek C, Hanenberg H, Rettie AE. CYP4V2 in Bietti’s crystalline dystrophy: ocular localization, metabolism of omega-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant. Mol Pharmacol. 2012;82:679–686.
15. Stark K, Guengerich FP. Characterization of orphan human cytochromes P450. Drug Metab Rev. 2007;39:627–637.
16. Kelly EJ, Nakano M, Rohatgi P, Yarov-Yarovoy V, Rettie AE. Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states. Mol Interv. 2011;11:124–132.
17. Xiao X, Mai G, Li S, Guo X, Zhang Q. Identification of CYP4V2 mutation in 21 families and overview of mutation spectrum in Bietti crystalline corneoretinal dystrophy. Biochem Biophys Res Commun. 2011;409:181–186.
18. Haddad NMN, Waked N, Bejjani R, et al. Clinical and molecular findings in three Lebanese families with Bietti crystalline dystrophy: report on a novel mutation. Mol Vis. 2012;18: 1182–1188.
19. Jin Z-B, Ito S, Saito Y, Inoue Y, Yanagi Y, Nao-i N. Clinical and molecular findings in three Japanese patients with crystalline retinopathy. Jpn J Ophthalmol. 2006;50:426–431.
20. Lai TYY, Ng TK, Tam POS, et al. Genotype phenotype analysis of Bietti’s crystalline dystrophy in patients with CYP4V2 mutations. Invest Ophthalmol Vis Sci. 2007;48:5212–5220.
21. Lee KY, Koh AH, Aung T, et al. Characterization of Bietti crystalline dystrophy patients with CYP4V2 mutations. Invest Ophthalmol Vis Sci. 2005;46:3812–3816.
22. Lin J, Nishiguchi KM, Nakamura M, Dryja TP, Berson EL, Miyake Y. Recessive mutations in the CYP4V2 gene in East Asian and Middle Eastern patients with Bietti crystalline corneoretinal dystrophy. J Med Genet. 2005;42:e38.
23. Liu DN, Liu Y, Meng XH, Yin ZQ. The characterization of functional disturbances in Chinese patients with Bietti’s crystalline dystrophy at different fundus stages. Graefes Arch Clin Exp Ophthalmol. 2011;250:191–200.
24. Mamatha G, Umashankar V, Kasinathan N, et al. Molecular screening of the CYP4V2 gene in Bietti crystalline dystrophy that is associated with choroidal neovascularization. Mol Vis. 2011;17:1970–1977.
25. Parravano M, Sciamanna M, Giorno P, Boninfante A, Varano M. Bietti crystalline dystrophy: a morpho-functional evaluation. Doc Ophthalmol. 2011;124:73–77.
26. Porter LF, Urquhart JE, O’Donoghue E, et al. Identification of a novel locus for autosomal dominant primary open angle glaucoma on 4q35.1-q35.2. Invest Ophthalmol Vis Sci. 2011; 52:7859–7865.
27. Shan M, Dong B, Zhao X, et al. Novel mutations in the CYP4V2 gene associated with Bietti crystalline corneoretinal dystrophy. Mol Vis. 2005;11:738–743.
28. Wada Y, Itabashi T, Sato H, Kawamura M, Tada A, Tamai M. Screening for mutations in CYP4V2 gene in Japanese patients with Bietti’s crystalline corneoretinal dystrophy. Am J Ophthalmol. 2005;139:894–899.
29. Wang Y, Guo L, Cai S-P, et al. Exome sequencing identifies compound heterozygous mutations in CYP4V2 in a pedigree with retinitis pigmentosa. PLoS One. 2012;7:e33673.
30. Yokoi Y, Sato K, Aoyagi H, Takahashi Y, Yamagami M, Nakazawa MA. Novel compound heterozygous mutation in the CYP4V2 gene in a Japanese patient with Bietti’s crystalline corneoretinal dystrophy. Case Rep Ophthalmol. 2011;2:296–301.
31. Yokoi Y, Nakazawa M, Mizukoshi S, Sato K, Usui T, Takeuchi K. Crystal deposits on the lens capsules in Bietti crystalline corneoretinal dystrophy associated with a mutation in the CYP4V2 gene. Acta Ophthalmol. 2009;88:607–609.
32. Zenteno JC, Ayala-Ramirez R, Graue-Wiechers F. Novel CYP4V2 gene mutation in a Mexican patient with Bietti’s crystalline corneoretinal dystrophy. Curr Eye Res. 2008;33: 313–318.
33. Song Y, Mo G, Yin G. A novel mutation in the CYP4V2 gene in a Chinese patient with Bietti’s crystalline dystrophy. Int Ophthalmol. 2013;33:269–276.
34. Yin H, Jin C, Fang X, et al. Molecular analysis and phenotypic study in 14 Chinese families with Bietti crystalline dystrophy. PLoS One. 2014;9:e94960.
35. Halford S, Liew G, Mackay DS, et al. Detailed phenotypic and genotypic characterization of Bietti crystalline dystrophy. Ophthalmology. 2014;1174–1184.
36. Bezemer ID, Bare LA, Doggen CJ, et al. Gene variants associated with deep vein thrombosis. JAMA. 2008;299: 1306–1314.
37. Lee J, Jiao X, Hejtmancik JF, Kaiser-Kupfer M, Chader GJ. Identification, isolation, and characterization of a 32-kDa fatty acid-binding protein missing from lymphocytes in humans with Bietti crystalline dystrophy (BCD). Mol Genet Metab. 1998;65:143–154.
38. Lee J, Jiao X, Hejtmancik JF, et al. The metabolism of fatty acids in human Bietti crystalline dystrophy. Invest Ophthalmol Vis Sci. 2001;42:1707–1714.
39. Lai TY, Chu KO, Chan KP, et al. Alterations in serum fatty acid concentrations and desaturase activities in Bietti crystalline dystrophy unaffected by CYP4V2 genotypes. Invest Ophthalmol Vis Sci. 2010;51:1092–1097.
40. Bernauer W, Daicker B. Bietti’s corneal-retinal dystrophy: a 16- year progression. Retina. 1992;12:18–20.
41. Furusato E, Cameron JD, Chan C-C. Evolution of cellular inclusions in Bietti’s crystalline dystrophy. Ophthalmol Eye Dis. 2010;2010:9–15.
42. Nakano M, Kelly EJ, Rettie AE. Expression and characterization of CYP4V2 as a fatty acid-hydroxylase. Drug Metab Dispos. 2009;37:2119–2122.
43. Mackay DS, Halford S. Focus on molecules: cytochrome P450 family 4, subfamily V, polypeptide 2 (CYP4V2). Exp Eye Res. 2011;102:111–112.
44. Crouthamel MH, Kelly EJ, Ho RJ. Development and characterization of transgenic mouse models for conditional gene knockout in the blood-brain and blood-CSF barriers. Transgenic Res. 2012;21:113–130.
45. Parkinson OT, Liggitt HD, Rettie AE, Kelly EJ. Generation and characterization of a Cyp4b1 null mouse and the role of CYP4B1 in the activation and toxicity of Ipomeanol. Toxicol Sci. 2013;134:243–250.
46. Matyash V, Liebisch G, Kurzchalia TV, Shevchenko A, Schwudke D. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J Lipid Res. 2008;49:1137–1146.
47. Alpers CE, Hudkins KL, Pritzl P, Johnson RJ. Mechanisms of clearance of immune complexes from peritubular capillaries in the rat. Am J Pathol. 1991;139:855–867.
48. Flurkey K, Currer JM, Harrison DE. The mouse in aging research. In: Fox JG, ed. The Mouse in Biomedical Research. 2nd ed. Burlington, MA: American College Laboratory Animal Medicine (Elsevier); 2007:637–372.
49. Curcio CA, Johnson M, Rudolf M, Huang JD. The oil spill in ageing Bruch membrane. Br J Ophthalmol. 2011;95:1638–1645.
50. Curcio CA, Johnson M, Huang JD, Rudolf M. Apolipoprotein Bcontaining lipoproteins in retinal aging and age-related macular degeneration. J Lipid Res. 2010;51:451–467.
51. Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res. 1983;22:79–131.
52. Weylandt KH, Chiu CY, Gomolka B, Waechter SF, Wiedenmann B. Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostaglandins Other Lipid Mediat. 2012;97:73–82.
53. Spite M, Claria J, Serhan CN. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab. 2014;19:21–36.
54. Duffield JS, Hong S, Vaidya VS, et al. Resolvin D series and Protectin D1 mitigate acute kidney injury. J Immunol. 2006; 177:5902–5911.
55. Wang Y, Wang VM, Chan CC. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye. 2011;25:127–139.
56. Young RW. Shedding of discs from rod outer segments in the rhesus monkey. J Ultrastruct Res. 1971;34:190–203.
57. Christmas P, Ursino SR, Fox JW, Soberman RJ. Expression of the CYP4F3 gene. Tissue-specific splicing and alternative promoters generate high and low K(m) forms of leukotriene B(4) omega-hydroxylase. J Biol Chem. 1999;274:21191–21199.
58. Mehlem A, Hagberg CE, Muhl L, Eriksson U, Falkevall A. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat Protoc. 2013;8: 1149–1154.